NEW YORK (GenomeWeb News) – Cancer Genetics has received CLIA and New York State approvals for the clinical use of its mature B-cell neoplasm array, or MatBA, for diffuse large B-cell lymphoma, the company said late Monday.

The MatBA-DLBCL array is to assist clinicians in the diagnosis and prognosis of DLBCL.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.